Kathie M. Bishop
Kathie M. Bishop, Ph.D. is the Chief Therapeutic Officer of the LouLou Foundation, with the goal to have meaningful treatments developed for CDKL5 deficiency disorder. Kathie has more than 20 years experience in leading translational research and drug development, with a focus on novel therapeutics in neurological and rare diseases. She has led all phases of research and development of therapeutics including genetic medicines (antisense oligonucleotides and siRNA, AAV gene therapy, CRISPR), small molecules, and large molecules and including leadership experience across research, preclinical development, and all stages of clinical development. Notably, Kathie led the late-stage development and FDA approval of DAYBUETM (trofinetide), the first and only approved treatment for Rett syndrome and led the global development of SPINRAZATM (nusinersen), the first approved treatment for Spinal Muscular Atrophy which was awarded the Prix Galien USA Award for Best Biotechnology Product in 2017. Kathie conducted post-doctoral work in Developmental Neurobiology at the Salk Institute for Biological Studies and obtained a Ph.D. in Neuroscience from the University of Alberta in Canada.